Additionally, Metellus et al. reported that high CD133 mRNA expression in a cohort of 48 consecutive primary GBM patients treated by chemoradiation with temozolomide, was a significant (p = 0.007) prognostic factor for adverse progression free and overall survival independent of resection (p = 0.012) and MGMT methylation status (p = 0.002) [20]. The gene discussed is PROM1; the disease is glioblastoma.